22UA:FRA
BioNTech SE - ADR
€ 78.95
arrow_downward
-0.19%(-0.15) 1D
10-р сарын 15, 15:25:01 (GMT+2) · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 22UA...
Open
€ 78.65
High
€ 79.70
Low
€ 78.60
Mkt. cap
22.53 тэрбум
Avg. vol.
1.41 мян
Volume
42.00
52-wk high
€ 105.50
52-wk low
€ 68.00
No. of employees
8 мян
Open
€ 78.65
High
€ 79.70
Low
€ 78.60
Mkt. cap
22.53 тэрбум
Avg. vol.
1.41 мян
Volume
42.00
52-wk high
€ 105.50
52-wk low
€ 68.00
No. of employees
8 мян
News stories
From web sources and news partners
ad-hoc-news.de
·
2 цагийн өмнө
BioNTech's Pipeline Reckoning: BNT113 Stumble and Insider Sales Keep the Stock 25% Below Its Peak
Pluang
·
19 цагийн өмнө
BioNTech shares drop 7.13% after trial failure raises concerns over oncology program claims
Simply Wall Street
·
1 өдрийн өмнө
BioNTech Stock Faces Questions After Cancer Trial Missed Progression Free Survival Goal
TradingKey
·
1 өдрийн өмнө
Biontech SE Stock (BNTX) Closed Down by 7.13% on Oct 13: Drivers Behind the Movement
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR